Philip Morris International upgraded by Societe Generale
$PM
Medicinal Chemicals and Botanical Products
Health Care
Societe Generale upgraded Philip Morris International from Sell to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2025 | $220.00 | Buy | Jefferies |
| 5/22/2025 | $195.00 | Buy | Needham |
| 4/25/2025 | $170.00 | Sell → Neutral | UBS |
| 3/14/2025 | Hold → Buy | Argus | |
| 1/16/2025 | $140.00 | Overweight | Morgan Stanley |
| 3/5/2024 | Buy → Hold | Argus | |
| 2/13/2024 | Sell → Hold | Societe Generale | |
| 1/23/2024 | $105.00 → $86.50 | Buy → Sell | UBS |
8-K - Philip Morris International Inc. (0001413329) (Filer)
25-NSE - Philip Morris International Inc. (0001413329) (Subject)
10-Q - Philip Morris International Inc. (0001413329) (Filer)
3 - Philip Morris International Inc. (0001413329) (Issuer)
4 - Philip Morris International Inc. (0001413329) (Issuer)
4 - Philip Morris International Inc. (0001413329) (Issuer)
MIAMI, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Long PM ETF (Ticker: ZYN). This fund provides investors with amplified 2X daily exposure to the performance of Philip Morris International Inc. (NYSE:PM), enabling retail investors to participate in the growth of a leading innovator without the need for a margin account. ZYN seeks to deliver daily investment results, before fees and expenses, of 200% of the daily performance of Philip Morris International Inc.. The Fund utilizes derivatives such as swaps and options to achieve its leveraged objectives, offering prec
Reaffirms 2025 Full-Year Forecast for Reported Diluted EPS of $7.24 to $7.37 and Adjusted Diluted EPS of $7.43 to $7.56, Representing Growth of 13% to 15%, 11.5% to 13.5% Excluding Currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) Chief Executive Officer, Jacek Olczak, will address investors today at the 2025 Barclays Global Consumer Staples Conference. "With strong volume momentum over the summer months, including IQOS and ZYN offtake, and despite increasing competition in smoke-free products, we are on track to deliver our full-year guidance of 13% to 15% adjusted diluted EPS growth in dollar terms, the strongest since 2011 excluding the pandemic recovery,"
Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live webcast of a fireside chat session with Jacek Olczak, Chief Executive Officer, at the 2025 Barclays Global Consumer Staples Conference at www.pmi.com/2025barclays on Tuesday, September 2, 2025, at approximately 11:15 a.m. ET. An archived copy of the webcast will be available for six months post-event. The webcast may also be accessed on mobile devices by downloading PMI's free Investor Relations Mobile App at www.pmi.com/irapp. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future
Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00
Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00
UBS upgraded Philip Morris International from Sell to Neutral and set a new price target of $170.00
Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex
Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what
In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002
Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 second quarter results.1 "Our business delivered very strong results in the second quarter, with record net revenues and exceptional growth in operating income and adjusted diluted EPS," said Jacek Olczak, Chief Executive Officer. "These results reflect excellent momentum in our multicategory smoke-free business, with a reacceleration of IQOS adjusted in-market sales growth and ZYN U.S. offtake growth, coupled with combustibles resilience. Given our strong year-to-date performance, we are raising our full-year guidance." _____________________________ 1 Explanation of PMI's use of non-GAAP me
Regulatory News: The Board of Directors of Philip Morris International Inc. (PMI) (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on July 15, 2025, to shareholders of record as of June 27, 2025. The ex-dividend date is June 27, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primar
Reaffirms 2025 Full-Year Forecast for Reported Diluted EPS of $7.01 to $7.14 and Adjusted Diluted EPS of $7.36 to $7.49, Representing Growth of 12% to 14%, 10.5% to 12.5% Excluding Currency Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 dbAccess Global Consumer Conference in Paris. The event will be webcast live in listen-only mode, beginning at approximately 11:15 a.m. CEST (5:15 a.m. EST), at www.pmi.com/2025dbaccess and on the PMI Investor Relations Mobile Application (www.pmi.com/irapp). An archived copy of the webcast will be available for approximately one year. 2025 Full-Ye
SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)
SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)
SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)